ArticleOncology letters2026
Effect of perioperative nutritional status, inflammatory response and postoperative chemotherapy on survival after gastrectomy for advanced gastric cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of numerous perioperative prognostic indicators for advanced gastric cancer, their relative predictive accuracy has not been compared. The present study investigated the association of these indicators and postoperative chemotherapy with patient survival in advanced gastric cancer. A total of 142 patients with stage II-IV gastric cancer who underwent gastrectomy with R0/R1 resection were examined. The preoperative modified Glasgow prognostic score (mGPS), controlling nutritional status score, CRP-to-albumin ratio, prognostic nutritional index and neutrophil-to-lymphocyte ratio was calculated. Postoperative serum CRP was evaluated as the CRPmax. Postoperative chemotherapy was administered according to the Japanese Gastric Cancer Treatment Guidelines. Patients were divided into chemotherapy and no chemotherapy groups, followed by propensity score matching to adjust for background factors. The endpoints were relapse-free survival (RFS) and overall survival (OS). Prognostic factors were evaluated using the Cox proportional hazard model. The OS and RFS were found to be improved in the chemotherapy group compared with the no chemotherapy group (P<0.05) and in the low mGPS group compared with the high mGPS group (P<0.05). Stepwise regression analysis identified the mGPS as the most reliable preoperative marker for both OS and RFS. Cox analysis of the matched groups revealed that postoperative chemotherapy was an independent prognostic factor for RFS and that mGPS was an independent prognostic factor for OS. A preoperative CRP of <0.3 mg/dl and a low mGPS score were found to be independent prognostic factors for RFS in the chemotherapy group. Overall, postoperative chemotherapy was found to reduce recurrence in advanced gastric cancer, while the preoperative mGPS was a strong prognostic marker for OS. Improving the preoperative mGPS may therefore improve both OS and the effectiveness of postoperative chemotherapy, but future large-scale studies are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.